COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a plant-based prescription drug, granted Orphan Drug Designation by FDA & EMA for treating rare pediatric diseases, including short bowel syndrome (SBS) & microvillus inclusion disease (MVID). Study presented at ELITE PED-GI Congress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Jaguar Health's crofelemer shows significant results in breast cancer patients for prophylaxis of diarrhea. Late-breaker abstracts on responder analysis and oral mucositis survey results accepted for MASCC's 2025 Annual Meeting -
-
-
COMMUNIQUÉ DE PRESSE
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Jaguar Health, Inc. (NASDAQ:JAGX) announces Napo Pharmaceuticals' participation in the 50th Oncology Nursing Society Congress to showcase Gelclair® for oral mucositis relief in cancer patients
